HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MBOAT2
membrane bound glycerophospholipid O-acyltransferase 2
Chromosome 2 · 2p25.1
NCBI Gene: 129642Ensembl: ENSG00000143797.13HGNC: HGNC:25193UniProt: B0AZU0
27PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
phosphatidylcholine acyl-chain remodeling1-acylglycerophosphocholine O-acyltransferase activity1-acylglycerophosphoethanolamine O-acyltransferase activity1-acylglycerophosphoserine O-acyltransferase activityhemangioma of subcutaneous tissuefrozen shoulderperipheral vascular diseaseovarian dysfunction
✦AI Summary

MBOAT2 is an acyltransferase that catalyzes the reacylation of lysophospholipids in the Lands cycle of phospholipid remodeling 1. It preferentially acylates lysophosphatidylethanolamine and lysophosphatidic acid, with oleoyl-CoA as its preferred acyl donor 1. Beyond canonical lipid remodeling, MBOAT2 functions as a ferroptosis suppressor by remodeling cellular phospholipid profiles in a manner independent of GPX4 or FSP1 2. Its ferroptosis-regulatory function is transcriptionally controlled by sex hormone receptors—estrogen receptor and androgen receptor—offering therapeutic potential in hormone-responsive cancers 2. MBOAT2 expression correlates with improved survival across multiple cancer types and associates with immune checkpoint regulation, suggesting roles in cancer immunity 3. In prostate cancer, MBOAT2 is identified as an AR-regulated mediator of ferroptosis resistance, making it a target for precision oncology approaches combining ferroptosis induction with androgen-targeted therapy 4. CircRNA derived from MBOAT2 locus promotes intrahepatic cholangiocarcinoma progression by stabilizing PTBP1 and regulating lipid metabolism reprogramming 5. Additionally, circRNA MBOAT2 regulates angiogenesis via the miR-495/NOTCH1 axis in coronary disease and pancreatic cancer contexts 67, and serves as a biomarker for cardiopulmonary adaptation in athletes 8.

Sources cited
1
MBOAT2 catalyzes acyl-CoA transfer to lysophospholipids in the Lands cycle, preferentially acylating LPE and LPA with oleoyl-CoA donor preference
PMID: 18772128
2
MBOAT2 suppresses ferroptosis via phospholipid remodeling independent of GPX4/FSP1, with transcriptional regulation by estrogen and androgen receptors
PMID: 37267948
3
MBOAT2 is highly expressed across cancer types, correlates with improved survival, and associates with immune cell infiltration and immune checkpoints
PMID: 40088361
4
MBOAT2 is an AR-regulated mediator of ferroptosis resistance in prostate cancer, representing a target for combination therapy with ferroptosis inducers
PMID: 40819692
5
CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma by stabilizing PTBP1 to facilitate FASN mRNA export, regulating lipid metabolism and redox homeostasis
PMID: 36635270
6
CircRNA MBOAT2 promotes angiogenesis via the miR-495/NOTCH1 axis and associates with myocardial perfusion improvement in coronary artery disease
PMID: 38255868
7
CircRNA MBOAT2 regulates pancreatic cancer progression and glutamine catabolism through the miR-433-3p/GOT1 axis
PMID: 33832516
8
CircRNA MBOAT2 is a stable plasma biomarker detecting cardiopulmonary adaptation after strenuous exercise in marathon runners
PMID: 32412780
Disease Associationsⓘ20
hemangioma of subcutaneous tissueOpen Targets
0.28Weak
frozen shoulderOpen Targets
0.26Weak
peripheral vascular diseaseOpen Targets
0.22Weak
ovarian dysfunctionOpen Targets
0.22Weak
placenta praeviaOpen Targets
0.21Weak
parasitic infectionOpen Targets
0.20Weak
cholelithiasisOpen Targets
0.19Weak
cardiac transplantOpen Targets
0.19Weak
complex regional pain syndromeOpen Targets
0.16Weak
type 1 diabetes nephropathyOpen Targets
0.16Weak
stomach diseaseOpen Targets
0.15Weak
neoplasmOpen Targets
0.09Suggestive
cancerOpen Targets
0.08Suggestive
pachyonychia congenitaOpen Targets
0.08Suggestive
non-small cell lung carcinomaOpen Targets
0.07Suggestive
Schnyder corneal dystrophyOpen Targets
0.07Suggestive
hypotensionOpen Targets
0.06Suggestive
prostatitisOpen Targets
0.06Suggestive
Ichthyosis - hepatosplenomegaly - cerebellar degenerationOpen Targets
0.04Suggestive
ichthyosis-hepatosplenomegaly-cerebellar degeneration syndromeOpen Targets
0.04Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
GPAT2Protein interaction98%DGKEProtein interaction95%PLPP2Protein interaction95%PLPP3Protein interaction95%LPIN2Protein interaction95%LPIN1Protein interaction95%
Tissue Expression6 tissues
Bone Marrow
100%
Brain
19%
Lung
9%
Ovary
8%
Heart
6%
Liver
1%
Gene Interaction Network
Click a node to explore
MBOAT2GPAT2DGKEPLPP2PLPP3LPIN2LPIN1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q6ZWT7
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.62LoF Tolerant
pLIⓘ
0.18Tolerant
Observed/Expected LoF0.42 [0.29–0.62]
RankingsWhere MBOAT2 stands among ~20K protein-coding genes
  • #12,600of 20,598
    Most Researched27
  • #4,350of 17,882
    Most Constrained (LOEUF)0.62 · top quartile
Genes detectedMBOAT2
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones.
PMID: 37267948
Cell · 2023
1.00
2
A defective lysophosphatidic acid-autophagy axis increases miscarriage risk by restricting decidual macrophage residence.
PMID: 35220880
Autophagy · 2022
0.90
3
CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma progression and lipid metabolism reprogramming by stabilizing PTBP1 to facilitate FASN mRNA cytoplasmic export.
PMID: 36635270
Cell Death Dis · 2023
0.80
4
Pan-cancer analysis predicts MBOAT2 as a potential new ferroptosis related gene immune checkpoint.
PMID: 40088361
Discov Oncol · 2025
0.70
5
Precision targeting of androgen receptor-ferroptosis crosstalk in prostate cancer: From mechanisms to therapeutic strategies.
PMID: 40819692
Pharmacol Res · 2025
0.60